Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A11 | Q9UPY5 | 13/20 | 0.80 |
| ▸ | VDAC2 | P45880 | 1/20 | 0.80 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1593568 | 0.92 | SLC7A11 (0.88) | SLC7A11VDAC2LMNAALDH1A1MAPK1 | |
| SCHEMBL4463410 | 0.90 | SLC7A11 (0.84) | SLC7A11VDAC2LMNAALDH1A1MAPK1 | |
| Erastin SCHEMBL31385520 | 0.89 | SLC7A11 (1.00) | SLC7A11VDAC2LMNAMAPK1 | |
| Erastin SCHEMBL29370998 | 0.89 | SLC7A11 (1.00) | SLC7A11VDAC2LMNAMAPK1 | |
| Erastin SCHEMBL22213543 | 0.89 | SLC7A11 (1.00) | SLC7A11VDAC2LMNAMAPK1 | |
| Erastin SCHEMBL4457820 | 0.89 | SLC7A11 (1.00) | SLC7A11VDAC2LMNAMAPK1 | |
| SCHEMBL14010407 | 0.88 | SLC7A11 (0.81) | SLC7A11VDAC2LMNAALDH1A1MAPK1 | |
| SCHEMBL4452788 | 0.87 | SLC7A11 (0.79) | SLC7A11VDAC2LMNAALDH1A1MAPK1 | |
| SCHEMBL4519119 | 0.84 | SLC7A11 (0.85) | SLC7A11VDAC2ENPP2LMNAMAPK1 | |
| SCHEMBL14010414 | 0.84 | SLC7A11 (0.81) | SLC7A11VDAC2ENPP2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009108384-A2 | COMPOUNDS AND COMPOSITIONS THAT CAUSE NON-APOPTOTIC CELL DEATH AND USES THEREOF | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009108384-A2 | COMPOUNDS AND COMPOSITIONS THAT CAUSE NON-APOPTOTIC CELL DEATH AND USES THEREOF | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-09-03 | — | — | WO | disclosed |
| US-20080299076-A1 | Compunds and compositions that cause non-apoptotic cell death and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080299076-A1 | Compunds and compositions that cause non-apoptotic cell death and uses thereof | BAD, CASP3, BAX | SLC7A11 2266/4885VDAC2 801/4885ENPP2 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.